• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intervention strategies for emerging viruses: use of antivirals

tetano

Editor, Senior Moderator
Curr Opin Virol. 2013 Apr 4. pii: S1879-6257(13)00025-4. doi: 10.1016/j.coviro.2013.03.001. [Epub ahead of print]
Intervention strategies for emerging viruses: use of antivirals.
Debing Y, Jochmans D, Neyts J.
Source

Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium.
Abstract

Today, small molecule antiviral drugs are available for the treatment of infections with herpesviruses, HIV, HBV and HCV as well as with influenza viruses. Ribavirin, a broad-spectrum (but aspecific) antiviral, has been approved for the treatment of infections with respiratory syncytial virus, HCV and Lassa virus. Yet, for many other viruses that cause life-threatening infections [most of which are considered emerging and/or neglected] there are no drugs available. Ideally, potent and broad-spectrum (i.e., pan-genus or pan-family virus activity) antiviral drugs should be developed whereby one drug could be used for the treatment of a number of such viral infections. We here review recent evolutions in the search for inhibitors of emerging and neglected RNA viruses.

Copyright ? 2013 Elsevier B.V. All rights reserved.

PMID:
23562753
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23562753
 
Back
Top Bottom